Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma - PubMed (original) (raw)
doi: 10.1038/leu.2010.108. Epub 2010 May 20.
K Rsitow, D J Inwards, S M Ansell, I N Micallef, P B Johnston, T M Habermann, T E Witzig, J P Colgan, G S Nowakowski, C A Thompson, S N Markovic
Affiliations
- PMID: 20485372
- DOI: 10.1038/leu.2010.108
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
L F Porrata et al. Leukemia. 2010 Jul.
Abstract
A specific predictor during routine follow-up to ascertain risk for relapse after standard chemotherapy in non-Hodgkin's lymphoma (NHL) has not been identified. Thus, we studied absolute lymphocyte count (ALC) as a marker of poststandard chemotherapy (rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP)) NHL relapse in patients with diffuse large B-cell lymphoma (DLBCL). ALC was obtained at the time of confirmed relapse and at last follow-up. From 2000 until 2006, 149 consecutive DLBCL patients, originally diagnosed, treated with R-CHOP and followed up at Mayo Clinic, Rochester, were included in this study. Patients at last follow-up without relapse (N=112) had a higher ALC compared with those with relapsed lymphoma ((N=37) median ALC x 10(9)/l of 1.43 (range: 0.33-4.0) versus 0.67 (range: 0.18-1.98), P<0.0001, respectively). ALC at the time of confirmed relapse was a strong predictor for relapse with an area under the curve =0.91 (P<0.0001). An ALC <0.96 x 10(9)/l at the time of confirmed relapse had a positive predictive value of 72% and a positive likelihood ratio of 7.4 to predict relapse after R-CHOP in DLBCL. Patients with an ALC>or=0.96 x 10(9)/l (N=103) had a cumulative incidence of relapse of 6 versus 79% with an ALC <0.96 x 10(9)/l (N=46) (P<0.0001). This study suggests that lymphopenia measured by ALC can be used as a marker to assess risk of DLBCL relapse during routine follow-up after standard chemotherapy.
Similar articles
- New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Porrata LF, et al. Biol Blood Marrow Transplant. 2010 Mar;16(3):376-83. doi: 10.1016/j.bbmt.2009.10.029. Epub 2009 Oct 31. Biol Blood Marrow Transplant. 2010. PMID: 19883776 - Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN. Porrata LF, et al. Am J Hematol. 2009 Feb;84(2):93-7. doi: 10.1002/ajh.21337. Am J Hematol. 2009. PMID: 19123458 - Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R. Guirguis HR, et al. Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Review. - Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH, Connors JM. Sehn LH, et al. Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34. Oncology (Williston Park). 2005. PMID: 15934515 Review.
Cited by
- Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.
Kusano Y, Yokoyama M, Terui Y, Nishimura N, Mishima Y, Ueda K, Tsuyama N, Yamauchi H, Takahashi A, Inoue N, Takeuchi K, Hatake K. Kusano Y, et al. Blood Cancer J. 2017 Apr 21;7(4):e558. doi: 10.1038/bcj.2017.37. Blood Cancer J. 2017. PMID: 28430176 Free PMC article. - Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis.
Mu S, Ai L, Fan F, Qin Y, Sun C, Hu Y. Mu S, et al. Cancer Cell Int. 2018 Aug 22;18:119. doi: 10.1186/s12935-018-0609-9. eCollection 2018. Cancer Cell Int. 2018. PMID: 30166942 Free PMC article. - Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK/T cell lymphoma.
Wang L, Wang JH, Wu-Xiao ZJ, Xia ZJ, Huang HQ, Lu Y. Wang L, et al. Tumour Biol. 2015 Mar;36(3):1747-53. doi: 10.1007/s13277-014-2776-1. Epub 2014 Oct 31. Tumour Biol. 2015. PMID: 25366140 - Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy.
Kim YR, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, Cheong JW, Min YH. Kim YR, et al. J Hematol Oncol. 2011 Aug 15;4:34. doi: 10.1186/1756-8722-4-34. J Hematol Oncol. 2011. PMID: 21843362 Free PMC article. - A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
Procházka V, Pytlík R, Janíková A, Belada D, Sálek D, Papajík T, Campr V, Fürst T, Furstova J, Trněný M. Procházka V, et al. PLoS One. 2014 Jul 24;9(7):e102594. doi: 10.1371/journal.pone.0102594. eCollection 2014. PLoS One. 2014. PMID: 25058337 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials